

Index

- Acemannan, 357
- Acquired immunodeficiency syndrome, *see*
AIDS entries
- Adefovir (PMEA), 127
- AIDS (acquired immunodeficiency syndrome), xi–xii, 405
- drug studies, SIV infection of macaques as model for, 121–138
- era, 6–7
- feline model for (FAIDS), 7
- historical perspective, 1–16
- macaque retrovirus models of, 10
- monkey species in research, 102–103
- murine model for (MAIDS), 7, 25
- pathogenesis studies, SIV model for, 101–116
- pediatric, animal model, 123
- SCID mice transplanted with human cells as small animal models in research, 81–95
- simian (SAIDS), 10
- AIDS pathogenesis studies, FIV as model for, 239–261
- AIDS-related complex (ARC) stage of infection, 241
- AIDS vaccine studies, FIV as model for, 293–327
- Altered antigen presentation, FIV, 254
- ALV (avian leukemia virus), 4
- AMD3100, 349–350
- Amphetamine, 275
- Anemia induced by EIAV, 371
- Animal cloning, 427
- Animal models
- ideal, 24
- of infection, ethical issues in use of, 405–422
- Animal models (*cont.*)
- need for, 121–123
- in research on HIV, 406–407
- Animal research
- future perspectives on, 425–428
- humane endpoints with, 419–420
- Animal retrovirus infections, xi
- Animal score sheets, 412–416
- Animal suffering, 410–419
- Antigen presentation, altered, FIV, 254
- Antigenic variation, 298–299
- Antimetabolites, 343
- Antiviral activity, noncytolytic, 250–251
- Antiviral drug resistance, SIV, 133–137
- Antiviral drug strategy, ideal, 121–122
- Antiviral drug studies, macaques in, 124–125
- Antiviral therapies, FIV and, 191–193
- Antivirals, true, 342
- APOBEC3G, 164–165
- ARC (AIDS-related complex) stage of infection, 241
- Astrocytes, 52–53
- Attenuated virus vaccines, FIV, 189–190, 321–322
- Avian leukemia virus (ALV), 4
- AZT (zidovudine), 127, 132–133
- in FIV, 191–192, 343–345
- B-cell numbers, 246
- BBB (blood brain barrier), 53–55
- B7 + CTLA4+ T-cell-induced anergy and apoptosis, 254–257
- BEA-005, 127
- Bicyclams, 342
- Binge use of methamphetamine, FIV model for, 286–287
- BIV (bovine immunodeficiency virus), 8, 32

- Blood brain barrier (BBB), 53–55
 BNR (broad neutralization resistance), 181
 BoLV (bovine leukemia virus), 5
 Bovine immunodeficiency virus (BIV), 8, 32
 Bovine leukemia virus (BoLV), 5
 Broad neutralization resistance (BNR), 181
- CAEV (caprine arthritis encephalitis virus), 8, 28, 391–392, *see also* Envelope glycoprotein of CAEV
 studies of structure of surface envelope glycoprotein, 391–401
 cAMP response element (CRE), 151
 Caprine arthritis encephalitis virus, *see* CAEV
- Cats
 domestic, 239
 FIV infection in, 296–297
 nondomestic, feline lentiviruses of, 195–198
 CD4+ cells, FIV, 243
 CD4+ T-cells, 14
 FIV, 248–251
 CD4+ T regulatory cell-mediated energy and apoptosis, 257–261
 CD8 response, 22
 CD8+ T-cells, FIV, 250–251
 Cell-associated virus vaccines, 308–311
 Cell-mediated immune (CMI) response, 251–252
 Cellular immune responses, 22, *see also* Immune responses
 Cellular immunity to FIV, 248–251
 CEM cells, 86
 Challenge
 enhancement of, by vaccination, 323–325
 mucosal, vaccination against, 325–326
 route of, 315–316
 Challenge systems, 302–303
 Challenge virus, dose of, 316
 Chemokine gradient, 46
 Chemokine receptor usage, FIV, 242
 Chemokine receptors, 47–48, 56–57
 Chemokines
 HIV-1 neuropathogenesis and, 62–64
 HIV coreceptors and, 57–59
 neural function and, 59–62
 neuronal, 60
 neuropathogenesis of HIV-1 infection and, 45–65
 neuroprotection and, 64–65
 overview, 55–65
 subfamilies, 56
 Chemotactic cytokines, *see* Chemokines
 Clade variations, HIV, 20
 Clades, 299–301
 Cloning, animal, 427
 CMI (cell-mediated immune) response, 251–252
 CRE (cAMP response element), 151
 CTL (cytotoxic T lymphocytes), 22, 250
 CTL response, 110–111
 Cynomolgus macaques, 103
 Cytokine alterations, FIV, 252–253
 Cytokines, virally induced, role of, in EIAV, 372–374
 Cytotoxic T lymphocytes, *see* CTL entries
- DdC (zalcitabine), 345–346
 DdI (didanosine), 345
 Didanosine (ddI), 345
 DNA proviral genes, 3
 DNA vectored vaccines, 304–307
 FIV, 188, 321–322
 Domestic cats, 239
 Drug abuse, 275
 AIDS and FIV model and, 275–287
 Drug resistance studies, SIV, 135–136
 D4T (stavudine), 345
 DU, EIAV, 385–386
- EIA (equine infectious anemia), 365
 EIAV (equine infectious anemia virus), 8, 30
 anemia induced by, 371
 cell tropism, 369–370
 disease induction by, 370–374
 DU, 385–386
 Env variation, 383–385
 genome organization, 366–369
 immune system alterations, 374
 LTR variation, 382–383
 as model for lentiviral pathogenesis, 365–386
 molecular characterization of virulence determinants, 378–386
 Rev variation and, 380–382
 role of virally induced cytokines in, 372–374
 S2 protein and, 379–380
 TAR (ETAR), 367
 thrombocytopenia induced by, 371–372
 vaccines, 376–378
 EIAV replication, immune responses that control, 374–376

- eMDM (equine monocyte-derived macrophages), 370
- Encephalopathy, SIV, 108–109
- Endogenous virogenes, 3
- Endpoints, humane, with animals, 419–420
- Enteropathy, SIV, 107–108
- Entry inhibitors, 348–350
- Env variation, EIAV, 383–385
- Envelope glycoprotein of CAEV, 391–401
- comparative structural model of, 394–400
 - domain model of, 398–399
 - experimental evidence of structural model, 399–400
 - glycosylation of, 393–394
 - partial structural model, 394–396
 - potential loop regions of, 397–398
 - primary structure of, 392–394
 - sequence variability of, 392–393
 - studies of structure of, 391–401
- Envelope proteins, 160
- EPO (erythropoietin), 354–355
- Equine infectious anemia (EIA), 365
- Equine infectious anemia virus, *see* EIAV *entries*
- Equine monocyte-derived macrophages (eMDM), 370
- Erythrophagocytosis, 371
- Erythropoietin (EPO), 354–355
- ETAR (EIAV TAR), 367
- Ethical framework to develop research strategies and project evaluation, 407–420
- Ethical issues in use of animal models of infection, 405–422
- Ethics committees, guidance for, 420–422
- FAIDS (feline model for AIDS), 7
- FC (fixed virus-infected cell) vaccines, 185
- Feline immunodeficiency virus, *see* FIV *entries*
- Feline infectious peritonitis (FIP), 335
- Feline interferon- α , 353
- Feline lentiviruses, of nondomestic cats, 195–198
- Feline model for AIDS (FAIDS), 7
- Feline mu opiate receptor (MOR), 281
- Feline response
- to methamphetamine, 284
 - to morphine, 280
- Filagrastrim, 354
- FIP (feline infectious peritonitis), 335
- FIV (feline immunodeficiency virus), xi–xii, 14–15, 30–31, 149–150, 242–246
- FIV (feline immunodeficiency virus) (*cont.*)
- altered antigen presentation, 254
 - antiviral therapies and, 191–193
 - attenuated virus vaccines, 189–190, 321–322
 - AZT in, 191–192, 343–345
 - CD4+ cells, 243
 - CD4+ T-cells, 248–251
 - CD8+ T-cells, 250–251
 - cell tropism, 242–244
 - cellular immunity to, 248–251
 - chemokine receptor usage, 242
 - clinical disease, 176–177
 - comparison of HIV-1 infection properties with, 167
 - comparison of HIV-1 replication properties with, 167
 - course of disease, 240–241
 - critical issues for vaccine development, 190–191
 - cytokine alterations, 252–253
 - development of model, 334–341
 - DNA vaccines, 188, 321–322
 - drugs of abuse and FIV model and, 275–287
 - epidemiology, 170–173
 - examples of vaccines, 317–326
 - genetic characteristics of, 279–280
 - genome, 295–296
 - genome organization and expression, 151–153
 - geographic distribution of subtypes, 161
 - humoral immune response, 246–248
 - immune responses to, 180–184, 246–251, 298
 - immunodeficiency, 177–180
 - immunological changes, 339–341
 - immunopathogenesis of infection, 251–261
 - inactivated virus vaccines, 317–320
 - infection in cats, 296–297
 - methamphetamine and, 283–287
 - as model for AIDS pathogenesis studies, 239–261
 - as model for AIDS vaccine studies, 293–327
 - as model for binge use of methamphetamine, 286–287
 - as model for HIV, 149–199
 - as model for HIV treatment, 333–358
 - as model for occasional opiate abuse, 282–283

- FIV (feline immunodeficiency virus) (*cont.*)
 as model for opiate addiction and withdrawal, 283
 natural history of infection, 240
 neurologic disease, 337–338
 neuropathogenesis, 277–278
 neutralizing antibodies, 247–248
 opiate exposure, effects of, in infected cats, 282
 opiates and, 280–283
 outlook for animal model, 198–199
 pathology, 177–180
 protein and peptide vaccines, 322
 provirus and virus load, 341
 receptor usage, 166–169, 244–245
 regulatory and accessory genes, 162–166
 relevance of, to HIV vaccination, 294–298
 stomatitis, 336–337
 structural and enzymatic proteins, 153–162
 subunit and peptide vaccines, 187
 T-cell-mediated immunopathology, 254–261
 transmission, 170–173
 transmission and pathogenesis, 277
 treatment studies, 341–358
 tropism, 166–170, 278–279
 tumors, 338–339
 vaccine development, 184–191
 vaccine development strategies, crucial factors in, 298–317
 vaccines examples of, 317–326 using live viral and bacterial vectors, 188–189
 viral clades, 245–246
 viral determinants for cell tropism, 169–170
 as viral vector, 193–195
 viral vectored vaccines, 323
 virion structure, 150–151
 virus-infected cell vaccines, 317–320
 virus infection and host responses, 173–184
 virus infection in cell culture, 173
 virus localization in host, 174–176
 WKV and fixed-cell vaccines, 185–187
 Fixed virus-infected cell (FC) vaccines, 185
 Foscarnet (PFA), 347–348
- G-CSF (granulocyte colony-stimulation factor), 354
 GALT (gut associated lymphoid tissue), 107
 Genome organization and expression, FIV, 151–153
 Glycoprotein, envelope surface (SU), 293
 Good laboratory-animal practice, 408
 gp120, 348–349
 Granulocyte colony-stimulation factor (G-CSF), 354
 Growth factors, 353–356
 Gut associated lymphoid tissue (GALT), 107
 GW420867, 127
- HAART (highly active anti-retroviral therapy), 20
 HAD (HIV-1-associated dementia), 45–47
 pathogenesis of, 48
 Heroin, 275
 Highly active anti-retroviral therapy (HAART), 20
 HIV (human immunodeficiency virus), xi–xii, 19–21
 advanced disease, 23
 animal model systems of diseases, 19–35
 animal models of infection, 9
 animals in research on, 406–407
 clade variations, 20
 coreceptors, chemokines and, 57–59
 discovery of, 7–8
 FIV as model for, 149–199
 infection, 333 in hu-PBL-SCID mouse model, 84–89
 life cycle, 122
 mouse models, 25–27
 neuropathogenesis, 48–55
 NSI (nonsyncytial-inducing), 84
 recombinants between SIV and (SHIVs), 13–14, 33
 SI (syncytial-inducing), 84
 treatment, FIV as model for, 333–358
 ungulate models, 27–30
 vaccination, relevance of FIV to, 294–298
 vaccine trials, 101
 vaccines, inactivated, 320
 virus replication, 425–426
- HIV-1-associated dementia, *see* HAD
 HIV-1 encephalitis (HIVE), 46, 48
 HIV-1 neuropathogenesis, chemokines and, 62–64
 HIV-1 pathogenesis, 21–23
 HIV-1 transmission, 21–22
 HIV-1 virus
 chemokines and neuropathogenesis of infection, 45–65
 comparison of FIV infection properties with, 167

- HIV-1 virus (*cont.*)
 comparison of FIV replication properties with, 167
- HIV-2 virus, 32
- HIVE (HIV-1 encephalitis), 46, 48
- HTLV (human T-cell leukemia virus), 1, 5–7
- Hu-PBL-SCID mouse model, 81–82
 HIV infection in, 84–89
 immunization studies in, 93–94
 major technical aspects, 82–84
 modified models of, 86–89
 studies of passive immunity in, 91–93
 therapy and immunization studies, 89–94
- Human immunodeficiency virus, *see* HIV entries
- Human interferon- α , 351–352
- Human-mouse chimeras, 27
- Human T-cell leukemia virus (HTLV), 1, 5–7
- Humane endpoints with animals, 419–420
- Humoral immune responses, 22
 FIV, 246–248
- Ideal animal model, 24
- Ideal antiviral drug strategy, 121–122
- IFNs, *see* Interferons
- IGF-1 (insulin-like growth factor-1), 355–356
- Illicit drug use, 275–276
- Immune responses
 to FIV, 180–184, 246–251, 298
 that control EIAV replication, 374–376
 to vaccination, 302
- Immune system, xi
- Immune system alterations, EIAV, 374
- Immunodeficiency lentiviruses, 30–33
- Immunogens, viral, 298–302
- Immunological changes, FIV, 339–341
- Immunomodulators, 350–358
- Immunomodulatory activity, drugs with, 356–358
- Immunopathogenesis of FIV infection, 251–261
- Immunopathology, T-cell-mediated, FIV, 254–261
- In vivo Models of HIV Disease and Control*, xi–xii
- Inactivated HIV vaccines, 320
- Inactivated virus vaccines, FIV, 317–320
- Inactivated whole virus vaccines, 308–311
- Infectious agents, pathogenic potential of, ix
- Insulin-like growth factor-1 (IGF-1), 355–356
- Interferons (IFNs), 351–353
 Type-I, 90
- Karnofsky's score, 334–335
- K65R isolates, SIV, 136–137
- Laboratory-animal practice, good, 408
- Lactoferrin, 358
- Lamivudine (3TC), 346
- LAV (lymphadenopathy virus), 7
- Lentivectors, 427
- Lentiviral pathogenesis, EIAV as model for, 365–386
- Lentivirus-derived vectors, 427
- Lentivirus genus of retroviruses, 8
- Lentivirus infections
 effects of methamphetamine on, 284–286
 effects of opiates on, 281–282
- Lentivirus persistence, 242
- Lentiviruses, xi
 feline, of nondomestic cats, 195–198
 immunodeficiency, 30–33
 vaccines against, 425
- Levamisole, 357–358
- LTR variation, EIAV, 382–383
- Lymphadenopathy virus (LAV), 7
- Macaque retrovirus models of AIDS, 10
- Macaques
 in antiviral drug studies, 124–125
 cynomolgus, 103
 rhesus, 102–103
 SIV infection of, as model for AIDS drug studies, 121–138
- Maedi-visna virus (MVV), 365
- MAIDS (murine model for AIDS), 7, 25
- Mammary tumor Type B retroviruses (MMTV), 3
- Mason Pfizer monkey virus (MPMV), 10
- MCP-1 (monocyte chemotactic protein-1), 53
- Methamphetamine, 275
 binge use of, FIV model for, 286–287
 effects of, on lentivirus infections, 284–286
 feline response to, 284
 FIV and, 283–287
- Microglia, 51
- MMTV (mammary tumor Type B retroviruses), 3

- Molecular characterization of virulence determinants, EIAV, 378–386
- Moloney sarcoma virus (MSV), 4
- Monkey species in AIDS research, 102–103
- Monocyte chemotactic protein-1 (MCP-1), 53
- Mononuclear phagocytes (MP), 22, 50–52
- MOR (feline mu opiate receptor), 281
- Morphine, feline response to, 280
- Mouse models
HIV, 25–27
transgenic, 25–27
- MP (mononuclear phagocytes), 22, 50–52
- MPMV (Mason Pfizer monkey virus), 10
- MSV (Moloney sarcoma virus), 4
- Mu opiate receptor (MOR), feline, 281
- Mucosal challenge, vaccination against, 325–326
- MuLV (murine leukemia Type C retroviruses), 3, 25
- Murine leukemia Type C retroviruses (MuLV), 3, 25
- Murine model for AIDS (MAIDS), 7, 25
- MVV (maedi-visna virus), 365
- Nef protein, SIV, 115
- Neural function, chemokines and, 59–62
- Neurologic disease, FIV, 337–338
- Neuronal chemokines, 60
- Neuroprotection, chemokines and, 64–65
- Neutralizing antibodies
FIV, 247–248
virus, 186
- NNRTI (non-nucleoside RT inhibitors), 124–125, 347–348
- Non-nucleoside RT inhibitors (NNRTI), 124–125, 347–348
- Noncytolytic antiviral activity, 250–251
- Nondomestic cats, feline lentiviruses of, 195–198
- Nonsyncytial-inducing (NSI) HIV, 84
- NRTI (nucleoside reverse transcriptase inhibitors), 124
- NSI (nonsyncytial-inducing) HIV, 84
- Nucleoside analogues, 342–347
- Nucleoside reverse transcriptase inhibitors (NRTI), 124
- Nucleosides, 343
- Occasional opiate abuse, FIV model for, 282–283
- Oncogenes, 3
- Open reading frames (ORFs), 151
- Opiate abuse, occasional, FIV model for, 282–283
- Opiate addiction and withdrawal, FIV model for, 283
- Opiate exposure, effects of, in FIV infected cats, 282
- Opiates
effects of, on lentivirus infections, 281–282
FIV and, 280–283
- Orf-A, 165–166
- ORFs (open reading frames), 151
- Pathogenic potential of infectious agents, ix
- Pediatric AIDS animal model, 123
- PET (positron emission tomography), 426–427
- PFA (foscarnet), 347–348
- Physiological responses by vertebrates, 410
- PMEA (adefovir), 127
- PMPA (tenofovir), 127
- Positron emission tomography (PET), 426–427
- Project evaluation, ethical framework to develop, 407–420
- Protein and peptide vaccines, FIV, 322
- Protovirus hypothesis, 3
- Provirus and virus load, FIV, 341
- Q151M mutation, 136
- RANTES (regulated upon activation normal T-cell expressed and secreted), 53
- Receptor usage, FIV, 244–245
- Recombinant protein, peptide, and nonviral vectored vaccines, 312–314
- Recombinant viral vectored vaccines, 304–307
- Regulated upon activation normal T-cell expressed and secreted (RANTES), 53
- Regulatory T-cell population (Treg), 257–261
- Research strategies, ethical framework to develop, 407–420
- Retroperitoneal fibromatosis (RF), 11
- Retrotransposons, 3
- Retrovirus infection and immunosuppression, animal models of, 6
- Retrovirus infections, animal, xi
- Retroviruses, 3
lentivirus genus of, 8
major discoveries in history of, 2

- Rev response element (RRE), 153
 Rev variation, EIAV and, 380–382
 Reverse transcriptase (RT), 3
 RF (retroperitoneal fibromatosis), 11
 Rhesus macaques, 102–103
 Ribavirin (RTCA), 346–347
 RNA tumor viruses, 2–3
 Rous sarcoma virus (RSV), 4
 RRE (Rev response element), 153
 RSV (Rous sarcoma virus), 4
 RT (reverse transcriptase), 3
 RTCA (ribavirin), 346–347
- S2 protein, EIAV and, 379–380
 SAIDS (simian AIDS), 10
 SCID-hu model, 82
 SCID (severe combined immunodeficient) mice, 81–82
 transplanted with human cells as small animal models in research, 81–95
 Score sheets, animal, 412–416
 SDF-1 (stromal cell-derived factor 1), 52
 Seroconversion reaction, acute, 22
 Serotypes, 300
 Severe combined immunodeficient (SCID) mice, *see* SCID mice
 SHIVs (recombinants between SIV and HIV), 13–14, 33
 SI (syncytial-inducing) HIV, 84
 Simian AIDS (SAIDS), 10
 Simian immunodeficiency virus, *see* SIV entries
 Simian retrovirus (SRV), 10–11
 SIV (simian immunodeficiency virus), xi, xii, 32–33, 102
 antiviral drug resistance, 133–137
 coreceptor usage and viral evolution, 113–114
 different types of disease progression, 104–105
 drug resistance studies, 135–136
 encephalopathy, 108–109
 enteropathy, 107–108
 examples of macaque studies with antiviral drugs, 128–129, 131
 infection of macaques as model for AIDS drug studies, 121–138
 key parameters to monitor infection, 126
 K65R isolates, 136–137
 macaque model, 11–14
 model for AIDS pathogenesis studies, 101–116
 natural course of infection, 104–109
 SIV (simian immunodeficiency virus) (*cont.*)
 nef protein, 115
 organ-specific manifestations, 106–109
 recombinants between HIV and (SHIVs), 13–14, 33
 selected aspects of pathogenicity, 109–115
 T-cell turnover, 111–113
 treatment of infection, 130, 132–133
 SIV Stm, 12–13, 103
 SIVcpz, 13
 SIVmac, 13, 102
 SIVmne, 102
 SIVsm, 12, 102
 SIVstm, 12–13, 102
 Speciesism, 406
 SRV (simian retrovirus), 10–11
 Stavudine (d4T), 345
 Stomatitis, FIV, 336–337
 Stromal cell-derived factor 1 (SDF-1), 52
 SU (envelope surface glycoprotein), 293
 Suffering, animal, 410–419
 Surface envelope glycoprotein, CAEV, *see* Envelope glycoprotein of CAEV
 Syncytial-inducing (SI) HIV, 84
- T-cell-induced anergy and apoptosis, B7 + CTLA4+, 254–257
 T-cell-mediated immunopathology, FIV, 254–261
 T-cell population, regulatory (Treg), 257–261
 T-cell turnover, SIV, 111–113
 T lymphocytes, cytotoxic, *see* CTL entries
 T regulatory cell-mediated anergy and apoptosis, CD4+, 257–261
 TAR, 152
 TAX, 5
 3TC (lamivudine), 346
 Tenofovir (PMPA), 127
 Thrombocytopenia induced by EIAV, 371–372
 TRAIL, 89
 Transduction, 427
 Transgenic mouse models, 25–27
 Treg (regulatory T-cell population), 257–261
 True antivirals, 342
 T20, 349
 Tumors, FIV, 338–339
- Ungulate models, HIV, 27–30
 V3 function, 58

- Vaccination
 - enhancement of challenge by, 323–325
 - immune responses to, 302
 - measurement of outcomes of, 317
 - against mucosal challenge, 325–326
- Vaccine development, FIV, 184–191
- Vaccine development strategies, FIV, crucial factors in, 298–317
- Vaccines
 - attenuated virus, FIV, 321–322
 - cell-associated virus, 308–311
 - DNA vectored, 304–307 FIV, 321–322
 - EIAV, 376–378
 - FIV attenuated virus, 189–190 DNA, 188
 - DNA vectored, 321–322 examples of, 317–326 using live viral and bacterial vectors, 188–189
 - fixed virus-infected cell (FC), 185
 - inactivated HIV, 320
 - inactivated virus, FIV, 317–320
 - inactivated whole virus, 308–311
 - against lentiviruses, 425
 - protein and peptide, FIV, 322
 - recombinant protein, peptide, and nonviral vectored, 312–314
 - recombinant viral vectored, 304–307
 - viral vectored, FIV, 323
 - virus-infected cell, FIV, 317–320
 - whole killed virus (WKV)-based, 185
- Vertebrates, physiological responses by, 410
- Viral clades, FIV, 245–246
- Viral determinants for cell tropism, FIV, 169–170
- Viral immunogens, 298–302
- Viral oncogene hypothesis, 3
- Viral replication cycle, inhibitors of, 342
- Viral vector, FIV as, 193–195
- Viral vectored vaccines, FIV, 323
- Virally induced cytokines, role of, in EIAV, 372–374
- Virion structure, FIV, 150–151
- Virogenes, endogenous, 3
- Virulence determinants, molecular characterization of, EIAV, 378–386
- Virulence of virus, 301–302
- Virus, virulence of, 301–302
- Virus Cancer Program (VCP), 1–7
- Virus-infected cell vaccines, FIV, 317–320
- Virus infection
 - in cell culture, FIV, 173
 - and host responses, FIV, 173–184
- Virus load, FIV, 341
- Virus localization in host, FIV, 174–176
- Virus neutralizing antibodies, 186
- Virus replication, HIV, 425–426
- Visna Maedi, 29–30
- Visna virus (VV), 8
- VV (visna virus), 8
- VVP (Virus Cancer Program), 1–7
- WHO (World Health Organization), 24
- Whole killed virus (WKV)-based vaccines, 185
- Whole virus vaccines, inactivated, 308–311
- WKV (whole killed virus)-based vaccines, 185
- World Health Organization (WHO), 24
- Xenochimeric model, 83
- Zalcitabine (ddC), 345–346
- Zidovudine, *see* AZT